...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Role of Mifepristone in treatment of uterine fibroid: an experience from tertiary care centre in South India
【24h】

Role of Mifepristone in treatment of uterine fibroid: an experience from tertiary care centre in South India

机译：米非司酮在子宫肌瘤治疗中的作用：南印度三级护理中心的经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Uterine fibroid are the most common benign tumour of the uterus and is seen in 20% of women in their reproductive age group. The aim of the study was to evaluate effect of Mifepristone on uterine fibroid with reference to reduction in size of fibroid and change in symptomatic profile. Methods: It is a hospital based interventional study conducted at KIMS Hubli hospital. 98 patients with symptomatic fibroid uterus were given 50mg of Mifepristone on alternate day for 3 months. Results: Mifepristone treatment significantly reduced mean PBAC score from baseline score of 212.61 to 20.39 at the end of 3rd month of therapy. Mean fibroid volume also reduced significantly from baseline value of 237.95cm3 to 30.45cm3 after 3 months of treatment. At the end of therapy hemoglobin was raised from 9.57g/dl at baseline to 10.42g/dl after 3 months of treatment. No major side effects were observed, and 7% patients had hysterectomy. Conclusions: Mifepristone is very useful option in perimenopausal women with symptomatic fibroid. It reduces fibroid size and its symptoms without any major side effects. However, future long term RCTs are needed to assess the safety and efficacy of Mifepristone.
机译：背景：子宫肌瘤是最常见的子宫良性肿瘤，在20岁的育龄妇女中可见。这项研究的目的是评估米非司酮对子宫肌瘤的作用，并涉及减少肌瘤大小和症状变化。方法：这是在KIMS Hubli医院进行的一项基于医院的干预研究。 98例有症状的肌瘤子宫患者隔天换用米非司酮50mg，持续3个月。结果：在治疗的第3个月末，米非司酮治疗将PBAC的平均得分从基线评分从212.61显着降低到20.39。治疗3个月后，平均肌瘤体积也从基线值237.95cm3显着降低到30.45cm3。治疗结束后3个月，血红蛋白从基线的9.57g / dl升至10.42g / dl。没有观察到主要的副作用，7％的患者接受了子宫切除术。结论：米非司酮对绝经期有症状肌瘤的妇女非常有用。它减少了肌瘤的大小及其症状，而没有任何重大的副作用。但是，需要未来的长期RCT来评估米非司酮的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号